These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 27716332)

  • 1. Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis.
    Bugatti S; Bogliolo L; Vitolo B; Manzo A; Montecucco C; Caporali R
    Arthritis Res Ther; 2016 Oct; 18(1):226. PubMed ID: 27716332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis.
    Amkreutz JAMP; de Moel EC; Theander L; Willim M; Heimans L; Nilsson JÅ; Karlsson MK; Huizinga TWJ; Åkesson KE; Jacobsson LTH; Allaart CF; Turesson C; van der Woude D
    Arthritis Rheumatol; 2021 Jun; 73(6):921-930. PubMed ID: 33314699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study.
    van Wesemael TJ; Ajeganova S; Humphreys J; Terao C; Muhammad A; Symmons DP; MacGregor AJ; Hafström I; Trouw LA; van der Helm-van Mil AH; Huizinga TW; Mimori T; Toes RE; Matsuda F; Svensson B; Verstappen SM; van der Woude D
    Arthritis Res Ther; 2016 Dec; 18(1):285. PubMed ID: 27906045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Anti-Citrullinated Protein Antibodies on Progressive Systemic Bone Mineral Density Loss in Patients With Early Rheumatoid Arthritis After Two Years of Treat-to-Target.
    Bugatti S; Bogliolo L; Manzo A; De Stefano L; Delvino P; Motta F; Montecucco C
    Front Immunol; 2021; 12():701922. PubMed ID: 34194443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-citrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients.
    Llorente I; Merino L; Ortiz AM; Escolano E; González-Ortega S; García-Vicuña R; García-Vadillo JA; Castañeda S; González-Álvaro I
    Rheumatol Int; 2017 May; 37(5):799-806. PubMed ID: 28243799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI-detected osteitis is not associated with the presence or level of ACPA alone, but with the combined presence of ACPA and RF.
    Boeters DM; Nieuwenhuis WP; Verheul MK; Newsum EC; Reijnierse M; Toes RE; Trouw LA; van der Helm-van Mil AH
    Arthritis Res Ther; 2016 Aug; 18():179. PubMed ID: 27485323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Titer-Dependent Effect of Anti-Citrullinated Protein Antibodies On Systemic Bone Mass in Rheumatoid Arthritis Patients.
    Orsolini G; Caimmi C; Viapiana O; Idolazzi L; Fracassi E; Gatti D; Adami G; Rossini M
    Calcif Tissue Int; 2017 Jul; 101(1):17-23. PubMed ID: 28246933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials.
    Aletaha D; Alasti F; Smolen JS
    Arthritis Res Ther; 2015 Aug; 17(1):229. PubMed ID: 26307354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study.
    Bøyesen P; Hoff M; Odegård S; Haugeberg G; Syversen SW; Gaarder PI; Okkenhaug C; Kvien TK
    Arthritis Res Ther; 2009; 11(4):R103. PubMed ID: 19570223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA.
    Hecht C; Englbrecht M; Rech J; Schmidt S; Araujo E; Engelke K; Finzel S; Schett G
    Ann Rheum Dis; 2015 Dec; 74(12):2151-6. PubMed ID: 25115448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of high titers of anti-carbamylated protein antibodies with decreased bone mineral density in early arthritis patients.
    Regueiro C; Ortiz AM; Boveda MD; Castañeda S; Gonzalez-Alvaro I; Gonzalez A
    PLoS One; 2018; 13(8):e0202583. PubMed ID: 30118518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgA rheumatoid factor is associated with bone mineral density preservation in rheumatoid arthritis.
    Sghiri R; Boumiza A; Benhassine H; Elamri N; Shakoor Z; Slama F; Almogren A; Harrabi I; Sahli J; Guaddah L; Zeglaoui H; Bouajina E
    Clin Rheumatol; 2021 Dec; 40(12):4879-4887. PubMed ID: 34282512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor.
    Ajeganova S; van Steenbergen HW; Verheul MK; Forslind K; Hafström I; Toes RE; Huizinga TW; Svensson B; Trouw LA; van der Helm-van Mil AH
    Ann Rheum Dis; 2017 Jan; 76(1):112-118. PubMed ID: 27117699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.
    Katchamart W; Koolvisoot A; Aromdee E; Chiowchanwesawakit P; Muengchan C
    Rheumatol Int; 2015 Oct; 35(10):1693-9. PubMed ID: 25903353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alveolar bone loss is associated with circulating anti-citrullinated protein antibody (ACPA) in patients with rheumatoid arthritis.
    Gonzalez SM; Payne JB; Yu F; Thiele GM; Erickson AR; Johnson PG; Schmid MJ; Cannon GW; Kerr GS; Reimold AM; Sokolove J; Robinson WH; Mikuls TR
    J Periodontol; 2015 Feb; 86(2):222-31. PubMed ID: 25299390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does information on novel identified autoantibodies contribute to predicting the progression from undifferentiated arthritis to rheumatoid arthritis: a study on anti-CarP antibodies as an example.
    Boeters DM; Trouw LA; van der Helm-van Mil AHM; van Steenbergen HW
    Arthritis Res Ther; 2018 May; 20(1):94. PubMed ID: 29724250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Autoantibodies Regulate Osteoclast Induced Bone Loss in Rheumatoid Arthritis.
    Steffen U; Schett G; Bozec A
    Front Immunol; 2019; 10():1483. PubMed ID: 31333647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis.
    Güler-Yüksel M; Bijsterbosch J; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Ronday HK; Peeters AJ; de Jonge-Bok JM; Breedveld FC; Dijkmans BA; Allaart CF; Lems WF
    Ann Rheum Dis; 2007 Nov; 66(11):1508-12. PubMed ID: 17456523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Only rheumatoid factor-positive subset of anti-citrullinated peptide/protein antibody-negative rheumatoid arthritis may seroconvert to anti-citrullinated peptide/protein antibody-positive.
    Hiwa R; Ohmura K; Nakabo S; Terao C; Murakami K; Nakashima R; Imura Y; Yukawa N; Yoshifuji H; Hashimoto M; Furu M; Ito H; Fujii T; Mimori T
    Int J Rheum Dis; 2017 Jun; 20(6):731-736. PubMed ID: 28198158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.